Summary & Overview
HCPCS J1427: Injection, viltolarsen, 10 mg
HCPCS Level II code J1427 designates a 10 mg injection of viltolarsen, a specialty injectable therapy. As a product-specific drug code, it enables standardized reporting of viltolarsen administration across outpatient and hospital settings and supports clinical documentation, medical necessity review, and pharmacy benefit coordination. Nationally, accurate use of J1427 matters for tracking utilization of a targeted therapy and for payer adjudication of claims for high-cost specialty medications.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how these payers typically interact with HCPCS drug J-codes for coverage determinations, prior authorization processes, and claims processing workflows.
Readers will find benchmarks and contextual information on coding and billing practices for specialty injectables, policy considerations relevant to drug-specific HCPCS codes, and clinical context for where viltolarsen administration occurs. The report highlights common documentation elements associated with injectable drug services and summarizes areas where payers commonly require supplemental clinical information. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1427 describes an injection of viltolarsen, 10 mg. This code represents a single-dose parenteral administration of the medication used in clinical management where viltolarsen is indicated.
Service Type: Drug administration (injectable therapy)
Typical Site of Service: Outpatient infusion/clinic setting or hospital outpatient department, reflecting sites where specialty injectable drugs are commonly administered.
Clinical & Coding Specifications
Clinical Context
A pediatric or young adult patient with genetically confirmed Duchenne muscular dystrophy (DMD) presents to an outpatient infusion center for scheduled treatment with the antisense oligonucleotide therapy viltolarsen. The medication is supplied as J1427 (injection, viltolarsen, 10 mg) and is administered via intravenous infusion or as prescribed by the manufacturer in a controlled clinical setting. The clinical workflow includes: pre-infusion assessment (weight, vital signs, review of laboratory tests including liver function and renal function), verification of diagnosis and prior authorization, medication preparation by pharmacy (dose calculation based on weight and vial count of J1427), placement of an IV line, infusion under nursing observation, monitoring for infusion-related reactions and adverse effects, post-infusion observation for a specified period, documentation of lot number and vial wastage, and billing using the J1427 HCPCS Level II code with appropriate modifiers and diagnosis linkage. Typical sites of service are outpatient infusion centers, hospital outpatient departments, or specialty ambulatory clinics. A typical patient scenario: a 9-year-old male with confirmed DMD receiving routine monthly infusion of viltolarsen with prior authorization approved by Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, or Medicare; nursing documents vitals and infusion tolerance, pharmacy documents vial lot and any discarded drug using modifier JW if applicable, and the billing office submits J1427 with the diagnosis and any applicable modifiers.
Coding Specifications
| Modifier |
|---|